Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension

被引:195
作者
Brown, DW
Giles, WH
Croft, JB
机构
[1] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA
[2] Ctr Dis Control & Prevent, Cardiovasc Hlth Branch, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA
关键词
D O I
10.1067/mhj.2000.111112
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Although associations between hypertension, left ventricular hypertrophy (LVH), and coronary heart disease (CHD) have been described, it is less clear whether LVH is associated with increased rates of CHD in the absence of hypertension. Methods we examined this association with Cox regression analyses of data from 7924 adults 25 to 74 years of age from the Second National Health and Nutrition Examination Survey (NHANES II) Mortality Study (1976 to 1992). Covariates included age, race, sex, history of cardiovascular diseases and diabetes, cholesterol, body moss index, blood pressure, and smoking. Results During 16.8 follow-up years, there were 462 (26%) deaths from CHD (ICD-9 410-414) and 667 (38%) deaths from diseases of the heart (ICD-9 390-398, 402, 404, 410-414, 415-417, 420-429). LVH prevalence was 13.3 per 1000 population. Hypertension prevalence was 29.1%. LVH prevalence was higher among hypertensive adults than among normotensive adults (29.9 vs 6.4 per 1000, P <.001). Persons with LVH were twice as likely to die of CHD (relative risk, 2.0; 95% confidence interval, 1.2, 3.5) and diseases of the heart (relative risk, 1.9, 95% confidence interval, 1.1, 3.0) after adjustment for hypertension and covariates. In age-adjusted predicted survivor, probability plots for CHD, and diseases of the heart, normotensives with LVH had survival similar to hypertensive adults with LVH and lower survival than normotensive and hypertensive adults with no LVH. Conclusions our results confirm previous findings that the presence of LVH is a strong predictor of future cardiovascular death. Although LVH appears to be rare among normotensives clinicians should be aware that such individuals may have on increased risk for death similar to that of hypertensive adults with LVH.
引用
收藏
页码:848 / 856
页数:9
相关论文
共 20 条
[1]   Validity of electrocardiographic estimates of left ventricular hypertrophy and mass in African Americans (The Charleston Heart Study) [J].
Arnett, DK ;
Rautaharju, P ;
Sutherland, S ;
Usher, B ;
Keil, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (09) :1289-+
[2]   Why is left ventricular hypertrophy so predictive of morbidity and mortality? [J].
Benjamin, EJ ;
Levy, D .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1999, 317 (03) :168-175
[3]   UTILITY OF THE NATIONAL DEATH INDEX FOR ASCERTAINMENT OF MORTALITY AMONG CANCER PREVENTION STUDY-II PARTICIPANTS [J].
CALLE, EE ;
TERRELL, DD .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1993, 137 (02) :235-241
[4]   IMPROVED SEX-SPECIFIC CRITERIA OF LEFT-VENTRICULAR HYPERTROPHY FOR CLINICAL AND COMPUTER INTERPRETATION OF ELECTROCARDIOGRAMS - VALIDATION WITH AUTOPSY FINDINGS [J].
CASALE, PN ;
DEVEREUX, RB ;
ALONSO, DR ;
CAMPO, E ;
KLIGFIELD, P .
CIRCULATION, 1987, 75 (03) :565-572
[5]  
Chen Daguang, 1993, Chinese Medical Sciences Journal, V8, P197
[6]   Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial [J].
Cheung, BMY ;
Lau, CP .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (02) :179-187
[7]   IS THE ELECTROCARDIOGRAM STILL USEFUL FOR DETECTION OF LEFT-VENTRICULAR HYPERTROPHY [J].
DEVEREUX, RB .
CIRCULATION, 1990, 81 (03) :1144-1146
[8]   Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease [J].
Ecder, T ;
Edelstein, CL ;
Chapman, AB ;
Johnson, AM ;
Tison, L ;
Gill, EA ;
Brosnahan, GM ;
Schrier, RW .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (05) :1113-1116
[9]   COMPARABILITY OF MORTALITY FOLLOW-UP BEFORE AND AFTER THE NATIONAL DEATH INDEX [J].
EDLAVITCH, SA ;
BAXTER, J .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1988, 127 (06) :1164-1178
[10]   POTENCY OF VASCULAR RISK-FACTORS AS THE BASIS FOR ANTIHYPERTENSIVE THERAPY [J].
KANNEL, WB .
EUROPEAN HEART JOURNAL, 1992, 13 :34-42